Payment overview · 2025
General Payments
$219.94
7 reported records · 5 companies
Healthcare provider profile · identity verified
Otis M Jones, MD
Allopathic & Osteopathic Physicians|Internal Medicine · BROOKLYN, NY · NPI 1861563538
Verified facts
What the public records show
CMS Open Payments records show Otis M Jones, MD received $219.94 in general payments during 2025 across 7 reported records.
Kestra Medical Technology Services, Inc. accounted for 38.0% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 8 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Eliquis, Ozempic, Rybelsus.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 45 claims for Ozempic by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Rybelsus as an associated drug or biological on 161257 records involving 55409 distinct recipient NPIs. Public Medicare Part D data also shows 38 claims for Rybelsus by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 128 claims for Eliquis by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Kestra Medical Technology Services, Inc. | Unresolved — no canonical attribution shown | $83.60 | 38.0% | 2 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $58.60 | 26.6% | 2 | 2025 |
| Medtronic, Inc. |
Medtronic, Inc. exact · evidence 2025-07-22 |
$27.04 | 12.3% | 1 | 2025 |
| Exact Sciences Corporation | Unresolved — no canonical attribution shown | $25.70 | 11.7% | 1 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $25.00 | 11.4% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $219.94 | 7 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| Assure WCD Normalized: assure wcd |
Device | Kestra Medical Technology Services, Inc. | $83.60 | 2 | 2025 |
Source payment records
|
|||||
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $58.60 | 2 | 2025 |
Source payment records
|
|||||
| Rybelsus Normalized: rybelsus |
Drug | Novo Nordisk Inc | $58.60 | 2 | 2025 |
Source payment records
|
|||||
| MINIMED 780G Normalized: minimed 780g |
Device | Medtronic, Inc. | $27.04 | 1 | 2025 |
Source payment records
|
|||||
| The Cologuard Plus Collection Kit Normalized: the cologuard plus collection kit |
Device | Exact Sciences Corporation | $25.70 | 1 | 2025 |
Source payment records
|
|||||
| ELIQUIS Normalized: eliquis |
Drug | PFIZER INC. | $25.00 | 1 | 2025 |
Source payment records
|
|||||
| NURTEC ODT Normalized: nurtec odt |
Drug | PFIZER INC. | $25.00 | 1 | 2025 |
Source payment records
|
|||||
| PAXLOVID Normalized: paxlovid |
Drug | PFIZER INC. | $25.00 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| ELIQUIS eliquis |
2025 | Eliquis | 2024 | 128 | exact normalized | Medicare Part D |
| Ozempic ozempic |
2025 | Ozempic | 2024 | 45 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| Rybelsus rybelsus |
2025 | Rybelsus | 2024 | 38 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
45 | suppressed by CMS |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Rybelsus open payments reported associated product |
CMS Open Payments — General Payments 161257 supporting records · 55409 recipient NPIs · example record 1188130076 |
Rybelsus · 2024 Exact normalized brand match · 1 Part D row |
38 | suppressed by CMS |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
128 | 32 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Amlodipine Besylate | Amlodipine Besylate | 574 | 178 |
| Atorvastatin Calcium | Atorvastatin Calcium | 559 | 176 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 252 | 70 |
| Metoprolol Succinate | Metoprolol Succinate | 246 | 75 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 236 | 72 |
| Metformin Hcl | Metformin Hcl | 220 | 68 |
| Vitamin D2 | Ergocalciferol (Vitamin D2) | 191 | 60 |
| Furosemide | Furosemide | 189 | 58 |
| Losartan Potassium | Losartan Potassium | 177 | 49 |
| Omeprazole | Omeprazole | 157 | 50 |
| Gabapentin | Gabapentin | 154 | 52 |
| Fluticasone Propionate | Fluticasone Propionate | 144 | 48 |
| Valsartan | Valsartan | 134 | 37 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 133 | 38 |
| Nifedipine Er | Nifedipine | 132 | 41 |
| Eliquis | Apixaban | 128 | 32 |
| Montelukast Sodium | Montelukast Sodium | 128 | 42 |
| Pantoprazole Sodium | Pantoprazole Sodium | 122 | 29 |
| Hydrochlorothiazide | Hydrochlorothiazide | 119 | 38 |
| Potassium Chloride | Potassium Chloride | 110 | 40 |
| Tamsulosin Hcl | Tamsulosin Hcl | 107 | 36 |
| Enalapril Maleate | Enalapril Maleate | 102 | 33 |
| Famotidine | Famotidine | 99 | 31 |
| Carvedilol | Carvedilol | 97 | 33 |
| Glipizide Er | Glipizide | 91 | 31 |
| Farxiga | Dapagliflozin Propanediol | 89 | 22 |
| Allopurinol | Allopurinol | 88 | 23 |
| Metoprolol Tartrate | Metoprolol Tartrate | 88 | 27 |
| Entresto | Sacubitril/Valsartan | 85 | 20 |
| Lisinopril | Lisinopril | 82 | 27 |
| Ezetimibe | Ezetimibe | 77 | 22 |
| Januvia | Sitagliptin Phosphate | 77 | 24 |
| Hydralazine Hcl | Hydralazine Hcl | 74 | 24 |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 72 | 20 |
| Simvastatin | Simvastatin | 69 | 23 |
| Spironolactone | Spironolactone | 68 | 21 |
| Valsartan-Hydrochlorothiazide | Valsartan/Hydrochlorothiazide | 68 | 20 |
| Ammonium Lactate | Ammonium Lactate | 65 | 29 |
| Atenolol | Atenolol | 65 | 18 |
| Breo Ellipta | Fluticasone/Vilanterol | 65 | 16 |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 63 | 23 |
| Ibuprofen | Ibuprofen | 63 | 24 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 63 | 16 |
| Meclizine Hcl | Meclizine Hcl | 63 | 19 |
| Alendronate Sodium | Alendronate Sodium | 61 | 24 |
| Mupirocin | Mupirocin | 60 | 18 |
| Single Use Swab | Alcohol Antiseptic Pads | 60 | 24 |
| Pravastatin Sodium | Pravastatin Sodium | 59 | 19 |
| Jardiance | Empagliflozin | 57 | 12 |
| Atenolol-Chlorthalidone | Atenolol/Chlorthalidone | 56 | 17 |
| Levocetirizine Dihydrochloride | Levocetirizine Dihydrochloride | 54 | 16 |
| Mirtazapine | Mirtazapine | 54 | 20 |
| Alcohol Prep Pads | Alcohol Antiseptic Pads | 53 | 22 |
| Basaglar Kwikpen U-100 | Insulin Glargine,hum.Rec.Anlog | 52 | 13 |
| Clopidogrel | Clopidogrel Bisulfate | 52 | 21 |
| Chlorthalidone | Chlorthalidone | 51 | 18 |
| Levothyroxine Sodium | Levothyroxine Sodium | 48 | 15 |
| Meloxicam | Meloxicam | 47 | 14 |
| Warfarin Sodium | Warfarin Sodium | 46 | suppressed |
| Ozempic | Semaglutide | 45 | suppressed |
| Donepezil Hcl | Donepezil Hcl | 44 | 18 |
| Ramipril | Ramipril | 43 | 12 |
| Xarelto | Rivaroxaban | 43 | suppressed |
| Diclofenac Sodium | Diclofenac Sodium | 42 | 17 |
| Levetiracetam | Levetiracetam | 42 | suppressed |
| Finasteride | Finasteride | 40 | 13 |
| Nano 2nd Gen Pen Needle | Pen Needle, Diabetic | 40 | 15 |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 39 | 17 |
| Colchicine | Colchicine | 38 | 12 |
| Duloxetine Hcl | Duloxetine Hcl | 38 | suppressed |
| Rybelsus | Semaglutide | 38 | suppressed |
| Amlodipine Besylate-Benazepril | Amlodipine Besylate/Benazepril | 37 | 11 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 37 | suppressed |
| Labetalol Hcl | Labetalol Hcl | 37 | 15 |
| Glipizide | Glipizide | 36 | 14 |
| Prednisone | Prednisone | 35 | 22 |
| Memantine Hcl | Memantine Hcl | 34 | suppressed |
| Easy Touch Alcohol Prep Pads | Alcohol Antiseptic Pads | 32 | 14 |
| Citalopram Hbr | Citalopram Hydrobromide | 31 | suppressed |
| Linzess | Linaclotide | 30 | suppressed |
| Metolazone | Metolazone | 30 | 11 |
| Novolog Flexpen | Insulin Aspart | 30 | suppressed |
| Clotrimazole | Clotrimazole | 29 | 12 |
| Ketoconazole | Ketoconazole | 29 | suppressed |
| Methylprednisolone | Methylprednisolone | 29 | 20 |
| Glimepiride | Glimepiride | 28 | suppressed |
| Nystatin | Nystatin | 28 | suppressed |
| Sucralfate | Sucralfate | 28 | suppressed |
| Valacyclovir | Valacyclovir Hcl | 27 | suppressed |
| Arnuity Ellipta | Fluticasone Furoate | 26 | suppressed |
| Torsemide | Torsemide | 26 | 11 |
| Hydrocortisone | Hydrocortisone | 25 | 14 |
| Janumet | Sitagliptin Phos/Metformin Hcl | 25 | suppressed |
| Klor-Con M20 | Potassium Chloride | 25 | 12 |
| Metformin Hcl Er | Metformin Hcl | 25 | suppressed |
| Azithromycin | Azithromycin | 23 | 19 |
| Glipizide-Metformin | Glipizide/Metformin Hcl | 23 | suppressed |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 22 | suppressed |
| Pioglitazone Hcl | Pioglitazone Hcl | 22 | suppressed |
| Folic Acid | Folic Acid | 21 | suppressed |
| Primidone | Primidone | 21 | suppressed |
| Acetaminophen-Codeine | Acetaminophen With Codeine | 20 | suppressed |
| Tradjenta | Linagliptin | 20 | suppressed |
| Clonidine | Clonidine | 19 | suppressed |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 19 | suppressed |
| Repaglinide | Repaglinide | 19 | suppressed |
| Trulicity | Dulaglutide | 19 | suppressed |
| Janumet Xr | Sitagliptin Phos/Metformin Hcl | 18 | suppressed |
| Azelastine Hcl | Azelastine Hcl | 17 | suppressed |
| Budesonide-Formoterol Fumarate | Budesonide/Formoterol Fumarate | 17 | suppressed |
| Lokelma | Sodium Zirconium Cyclosilicate | 17 | suppressed |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 17 | 11 |
| Tresiba Flextouch U-100 | Insulin Degludec | 17 | suppressed |
| Amiodarone Hcl | Amiodarone Hcl | 16 | suppressed |
| Clobetasol Propionate | Clobetasol Propionate | 16 | suppressed |
| Doxazosin Mesylate | Doxazosin Mesylate | 16 | suppressed |
| Sevelamer Carbonate | Sevelamer Carbonate | 16 | suppressed |
| Sildenafil Citrate | Sildenafil Citrate | 16 | suppressed |
| Tacrolimus | Tacrolimus | 16 | suppressed |
| Easy Comfort Pen Needle | Pen Needle, Diabetic | 15 | suppressed |
| Fluconazole | Fluconazole | 15 | suppressed |
| Fosinopril Sodium | Fosinopril Sodium | 15 | suppressed |
| Methimazole | Methimazole | 15 | suppressed |
| Ultra-Fine Nano Pen Needle | Pen Needle, Diabetic | 15 | suppressed |
| Alcohol Pads | Alcohol Antiseptic Pads | 14 | suppressed |
| Calcitriol | Calcitriol | 14 | suppressed |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 14 | suppressed |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 14 | suppressed |
| Epinephrine | Epinephrine | 13 | suppressed |
| Flunisolide | Flunisolide | 13 | suppressed |
| Irbesartan | Irbesartan | 13 | suppressed |
| True Comfort Pro Alcohol Pads | Alcohol Antiseptic Pads | 13 | suppressed |
| Bisoprolol-Hydrochlorothiazide | Bisoprolol/Hydrochlorothiazide | 12 | suppressed |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 12 | suppressed |
| Ultra-Fine Short Pen Needle | Pen Needle, Diabetic | 12 | suppressed |
| Amoxicillin | Amoxicillin | 11 | suppressed |
| Cilostazol | Cilostazol | 11 | suppressed |
| Nitroglycerin Patch | Nitroglycerin | 11 | suppressed |
| Tramadol Hcl | Tramadol Hcl | 11 | suppressed |
| Vascepa | Icosapent Ethyl | 11 | suppressed |
| Vemlidy | Tenofovir Alafenamide | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $219.94 · 7 records | Kestra Medical Technology Services, Inc. | Assure WCD, ELIQUIS, MINIMED 780G, NURTEC ODT, Ozempic, PAXLOVID, Rybelsus, The Cologuard Plus Collection Kit | 3 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Eliquis play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with Novo Nordisk Inc?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error